NeuroVive Completes Closure Of Lyon Subsidiary

LUND, Sweden--(BUSINESS WIRE)--Regulatory News:

The closure of the subsidiary NeuroVive (STO:NVP) France SARL is a natural consequence of the company’s previously communicated decision that it will not pursue development of CicloMulsion®.

Accordingly, all agreements related to the research partnership with Hospices Civils de Lyon (HCL) and Professor Michel Ovize, including the OPeRa (Organ Protection & Replacement) have been terminated.

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, drug development and production expertise, as well as commercial partners.

NeuroVive has a project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to neurological and metabolic diseases.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48

www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on Oct 25, 2016.

This information was brought to you by Cision http://news.cision.com